200 Greenhill Road
Eastwood, SA 5063
61 8 8150 7400
|Mr. Adrian Hinton BEC, F.C.A.||Acting Chief Financial Officer||323.78k||N/A||1952|
|Mr. Connor Bernstein M.Sc.||VP of Strategy & Corp. Devel.||344.98k||N/A||1988|
|Dr. Spyridon Papapetropoulos M.D., Ph.D.||CEO, Pres & Director||N/A||N/A||1974|
|Prof. Paul Rolan D.C.P.S.A., F.F.P.M., F.R.A.C.P., M.B.B.S., M.D.||Consultant Chief Medical Officer of Clinical Neuroscience||N/A||N/A||N/A|
|Ms. Suzanne Irwin B.Com., FCIS||Company Sec.||N/A||N/A||N/A|
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.
Bionomics Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.